Next Article in Journal
Racial Differences in Functional and Sleep Outcomes with Positive Airway Pressure Treatment
Previous Article in Journal
Detection of Changes on Parameters Related to Heart Rate Variability after Applying Current Interferential Therapy in Subjects with Non-Specific Low Back Pain
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 11
Issue 12
10.3390/diagnostics11122170
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

by
Takayuki Takeda
1,*,
Tadaaki Yamada
2,
Keiko Tanimura
1,
Takayuki Nakano
1,
Masaki Ishida
2,
Yusuke Tachibana
3,
Shinsuke Shiotsu
3,
Shigeto Horiuchi
4,
Makoto Hibino
4,
Asuka Okada
5,
Yusuke Chihara
6 and
Koichi Takayama
2
1
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan
2
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
3
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan
4
Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Fujisawa 251-0041, Japan
5
Department of Respiratory Medicine, Saiseikai Suita Hospital, Suita 564-0013, Japan
6
Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2021, 11(12), 2170; https://doi.org/10.3390/diagnostics11122170
Submission received: 17 October 2021 / Revised: 17 November 2021 / Accepted: 22 November 2021 / Published: 23 November 2021
(This article belongs to the Section Pathology and Molecular Diagnostics)
Browse Figures
Review Reports Versions Notes

Abstract

The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in patients with several cancers, their usefulness in targeted therapies is scarce, and their significance has never been reported in patients receiving first-line treatment with alectinib. Meanwhile, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) has been investigated during crizotinib treatment. This multicenter retrospective study evaluated 42 consecutive Japanese patients with ALK-positive NSCLC who received first-line treatment with alectinib. Immunological and nutritional markers were evaluated at baseline and 3 weeks after alectinib introduction, and their significance in predicting progression-free survival (PFS) was explored. PFS duration was significantly associated with baseline PLR (hazard ratio (HR): 2.49, p = 0.0473), systemic immune-inflammation index (SII; HR: 2.65, p = 0.0337), prognostic nutrition index (PNI; HR: 4.15, p = 0.00185), and the 3-week values for SII (HR: 2.85, p = 0.0473) and PNI (HR: 3.04, p = 0.0125). Immunological and nutritional markers could be useful in predicting the outcomes of first-line treatment with alectinib. Since PLR and SII consist of platelet counts, platelet count could be an important constituent of these markers.
Keywords: alectinib; anaplastic lymphoma kinase (ALK); non-small-cell lung cancer; platelet-to-lymphocyte ratio (PLR); systemic immune-inflammation index (SII) alectinib; anaplastic lymphoma kinase (ALK); non-small-cell lung cancer; platelet-to-lymphocyte ratio (PLR); systemic immune-inflammation index (SII)

Share and Cite

MDPI and ACS Style

Takeda, T.; Yamada, T.; Tanimura, K.; Nakano, T.; Ishida, M.; Tachibana, Y.; Shiotsu, S.; Horiuchi, S.; Hibino, M.; Okada, A.; et al. Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics 2021, 11, 2170. https://doi.org/10.3390/diagnostics11122170

AMA Style

Takeda T, Yamada T, Tanimura K, Nakano T, Ishida M, Tachibana Y, Shiotsu S, Horiuchi S, Hibino M, Okada A, et al. Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics. 2021; 11(12):2170. https://doi.org/10.3390/diagnostics11122170

Chicago/Turabian Style

Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, Takayuki Nakano, Masaki Ishida, Yusuke Tachibana, Shinsuke Shiotsu, Shigeto Horiuchi, Makoto Hibino, Asuka Okada, and et al. 2021. "Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib" Diagnostics 11, no. 12: 2170. https://doi.org/10.3390/diagnostics11122170

APA Style

Takeda, T., Yamada, T., Tanimura, K., Nakano, T., Ishida, M., Tachibana, Y., Shiotsu, S., Horiuchi, S., Hibino, M., Okada, A., Chihara, Y., & Takayama, K. (2021). Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics, 11(12), 2170. https://doi.org/10.3390/diagnostics11122170

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop